At.las ATMP, your primary contact point for ATMP-driven research & innovation in Antwerp
Antwerp is a uniquely integrated European hub for cell and gene therapy, covering the full value chain from research and clinical trials to GMP manufacturing, specialized logistics, and advanced hospital care. By bringing together scientific innovation, translational development, and clinical implementation within one connected ecosystem, at.las ATMP ensures efficient bench-to-bedside translation and delivers cutting-edge cell therapies to patients.
A closer look at the Antwerp ATMP ecosystem
Network
✓ 2 knowledge institutions (UAntwerp, VITO)
✓ 1 university hospital (UZA) and 12 general hospitals
✓ 2 CDMO’s (anicells, Etherna)
Research
✓ Dendritic Cell Vaccination in Cancer and Autoimmune Diseases
✓ CAR-programs in Cancer
✓ Gentherapies in genetic sensorineural deafness (DFNA)
✓ Tissue-Engineered Products for Corneal Diseases
Clinical Trials
✓ 25% of ATMP studies in Belgium in 2023
✓ 12 investigator-driven studies
✓ 5 industry-driven studies
✓ 1 government-driven studies
Manufacturing
✓ > 200 individual patient batches delivered since 2015
✓ 350m2 cleanrooms for cell therapeutic productions
Latest News
- Announcing the 5th edition of the GMP for ATMP Summer School
From October 14–16 2026, the 5th edition of the GMP… Read more: Announcing the 5th edition of the GMP for ATMP Summer School - Connect with at.las ATMP at Knowledge for Growth!
Curious about opportunities in the cell and gene therapy domain?… Read more: Connect with at.las ATMP at Knowledge for Growth! - A New Step Forward in Multiple Sclerosis Research: Launch of the LUMINA-MS Clinical Trial
On April 20, 2026, an important milestone was reached in… Read more: A New Step Forward in Multiple Sclerosis Research: Launch of the LUMINA-MS Clinical Trial